[VIEW] agent=Payer Contracting & Finance Manager | scenario_id=120 | rounds=20

--- Round 0 ---
[R0.1] Risk & Compliance Officer (speak, public): To ensure we're aligned on launching the systemwide pharmacist-led telehealth anticoagulation management service with optional home INR monitoring, can we first discuss the current state of our clinical program design and operational readiness?
[R0.2] Pharmacy Clinical Lead (Anticoagulation Services) (speak, public): Our pilot outcomes for the tele-anticoagulation management service showed promising results, with Time in Therapeutic Range (TTR) improving from 52% to 68% across 2 clinics and 180 patients. We estimate that there are 640 eligible patients per quarter, with a pilot enrollment rate of 28%. I'd be happy to discuss the clinical program design and operational readiness in more detail.
[R0.3] Payer Contracting & Finance Manager (speak, public): To assess financial viability, can you share the expected demand for the telehealth anticoagulation management service and the anticipated staffing intensity? Additionally, are there any specific operational or clinical concerns that could impact our financial projections or contractual agreements?

--- Round 1 ---
[R1.1] Risk & Compliance Officer (speak, public): To better understand the operational readiness, can you elaborate on how the pilot program handled high-risk clinical situations and what measures were taken to ensure patient safety? Additionally, I'd like to know if there were any notable challenges in scaling the service.
[R1.2] Pharmacy Clinical Lead (Anticoagulation Services) (speak, public): Regarding the expected demand and staffing intensity, our pilot data suggests a significant interest in the telehealth anticoagulation management service, with an enrollment rate of 28% among eligible patients. For staffing, our model indicates that per 500 active patients, we require 1.8 pharmacist FTE and 0.6 RN FTE. Patient satisfaction has been high, with an overall rating of 4.6/5, although we've encountered some connectivity issues reported by 6% of patients. As for operational and clinical concerns, we've implemented measures to ensure patient safety, and I'd be happy to discuss those in more detail, particularly with regards to high-risk clinical situations and scaling the service.
[R1.3] Payer Contracting & Finance Manager (speak, public): Based on the information provided, it seems that the demand and staffing intensity are clearer. To further assess financial viability, can you confirm if there are any specific contractual or operational concerns that could impact our reimbursement model or create delays in implementation? Additionally, I'd like to understand more about the clinical dosing rules and how strict they are in practice.

--- Round 2 ---
[R2.1] Risk & Compliance Officer (speak, public): To ensure we're making an informed decision, can you clarify how the clinical dosing rules are applied in practice, particularly for high-risk patients? Additionally, I'd like to understand if there are any contractual constraints from payers that could impact our reimbursement model or create implementation delays.
[R2.2] Pharmacy Clinical Lead (Anticoagulation Services) (speak, public): To address the clinical dosing rules and their application in practice, I can share that our service has been designed with strict protocols to ensure patient safety, particularly for high-risk patients. However, I must emphasize that certain specifics, such as our critical INR escalation threshold, are sensitive and not publicly shared. I can assure you that we have robust measures in place. Regarding contractual constraints from payers, I believe our Payer Contracting & Finance Manager would be better positioned to provide insights on potential reimbursement model impacts or implementation delays.
[R2.3] Payer Contracting & Finance Manager (speak, public): To address the concerns regarding contractual constraints from payers and potential impacts on our reimbursement model, I can confirm that our current reimbursement model is based on a per-episode reimbursement of $62, with a projected volume of 9,600 episodes per year. We also have an opportunity to earn a quality incentive bonus of $250,000 if we meet the target TTR of ≥65% for the covered population. Regarding operational delays, I haven't identified any major concerns, but I'd like to confirm with you both that there are no hidden patient-safety exposures or overly complex clinical dosing rules that could impact our financial projections or contractual agreements.

--- Round 3 ---
[R3.1] Risk & Compliance Officer (speak, public): To summarize our discussion, we have a promising clinical program design with improved TTR and patient satisfaction, and a clear understanding of operational readiness and staffing intensity. From a risk and compliance perspective, I've confirmed that we have robust measures in place for patient safety, particularly for high-risk patients. However, I'd like to highlight that our vendor security due diligence for the home INR platform revealed some concerns, such as a security assessment score of 78/100 and a SOC 2 Type II report that is 19 months old. I'd like to request that we revisit the Business Associate Agreement with the vendor to address the outstanding clauses. Additionally, I'd appreciate it if we could discuss potential mitigation strategies for the identified security risks.
[R3.2] Pharmacy Clinical Lead (Anticoagulation Services) (speak, public): To address the concerns raised by Risk & Compliance Officer regarding the vendor security due diligence for the home INR platform, I agree that revisiting the Business Associate Agreement is a prudent step. Additionally, we should discuss potential mitigation strategies for the identified security risks to ensure we're adequately addressing them. From a clinical perspective, we've designed our service with patient safety in mind, and I'm confident in our ability to manage high-risk patients. I'd like to summarize our key findings and recommendations to ensure we're aligned on the next steps for launching the systemwide pharmacist-led telehealth anticoagulation management service.
[R3.3] Payer Contracting & Finance Manager (speak, public): To summarize our discussion on the financial viability and contractual readiness of the systemwide pharmacist-led telehealth anticoagulation management service, we have a clear understanding of the reimbursement model, with a per-episode reimbursement of $62 and a projected volume of 9,600 episodes per year. We also have a quality incentive opportunity of $250,000 if we meet the target TTR of ≥65%. From a financial perspective, our total cost is estimated at $940,000 per year, with a staffing component of $690,000. Given the information shared, I believe we have a solid foundation to assess the financial sustainability of the program. I'd like to confirm that we're aligned on the next steps and the potential risks associated with the vendor security due diligence for the home INR platform.

--- Round 4 ---
[R4.1] Risk & Compliance Officer (speak, public): To finalize our discussion on launching the systemwide pharmacist-led telehealth anticoagulation management service, I'd like to summarize the key findings: we've confirmed a robust clinical program design, operational readiness, and a clear understanding of the financial sustainability. However, we need to address the vendor security due diligence concerns and revisit the Business Associate Agreement. I recommend we move forward with the launch, conditional on resolving these outstanding risk and compliance issues. Let's discuss the next steps and potential mitigation strategies for the identified security risks.
[R4.2] Pharmacy Clinical Lead (Anticoagulation Services) (speak, public): To summarize our discussion, we have a robust clinical program design with improved TTR and patient satisfaction, a clear understanding of operational readiness and staffing intensity, and a financially sustainable model. I agree with Risk & Compliance Officer's recommendation to move forward with the launch, conditional on resolving the outstanding risk and compliance issues related to the vendor security due diligence for the home INR platform. Let's work together to revisit the Business Associate Agreement and discuss potential mitigation strategies for the identified security risks. I recommend we schedule a follow-up meeting to finalize the launch plan and address the outstanding issues.
[R4.3] Payer Contracting & Finance Manager (speak, public): To finalize our discussion, I agree that we have a robust clinical program design and a financially sustainable model. However, we need to address the vendor security due diligence concerns and revisit the Business Associate Agreement. I recommend we move forward with the launch, conditional on resolving these outstanding risk and compliance issues. Let's work together to discuss potential mitigation strategies for the identified security risks and schedule a follow-up meeting to finalize the launch plan.

--- Round 5 ---
[R5.1] Risk & Compliance Officer (speak, public): To finalize our discussion, I recommend that we move forward with launching the systemwide pharmacist-led telehealth anticoagulation management service, conditional on resolving the outstanding risk and compliance issues related to the vendor security due diligence for the home INR platform. Let's schedule a follow-up meeting to revisit the Business Associate Agreement and discuss potential mitigation strategies for the identified security risks.
[R5.2] Pharmacy Clinical Lead (Anticoagulation Services) (speak, public): I agree that we've made significant progress in our discussion. To finalize, I recommend that we move forward with launching the systemwide pharmacist-led telehealth anticoagulation management service, conditional on resolving the outstanding risk and compliance issues related to the vendor security due diligence for the home INR platform. Let's schedule a follow-up meeting to revisit the Business Associate Agreement and discuss potential mitigation strategies for the identified security risks.
[R5.3] Payer Contracting & Finance Manager (speak, public): I agree that we've made significant progress in our discussion. To finalize, I recommend that we move forward with launching the systemwide pharmacist-led telehealth anticoagulation management service, conditional on resolving the outstanding risk and compliance issues related to the vendor security due diligence for the home INR platform. Let's schedule a follow-up meeting to revisit the Business Associate Agreement and discuss potential mitigation strategies for the identified security risks.

--- Round 6 ---
[R6.1] Risk & Compliance Officer (leave, public): 
[R6.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R6.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 7 ---
[R7.1] Risk & Compliance Officer (leave, public): 
[R7.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R7.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 8 ---
[R8.1] Risk & Compliance Officer (leave, public): 
[R8.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R8.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 9 ---
[R9.1] Risk & Compliance Officer (leave, public): 
[R9.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R9.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 10 ---
[R10.1] Risk & Compliance Officer (leave, public): 
[R10.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R10.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 11 ---
[R11.1] Risk & Compliance Officer (leave, public): 
[R11.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R11.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 12 ---
[R12.1] Risk & Compliance Officer (leave, public): 
[R12.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R12.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 13 ---
[R13.1] Risk & Compliance Officer (leave, public): 
[R13.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R13.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 14 ---
[R14.1] Risk & Compliance Officer (leave, public): 
[R14.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R14.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 15 ---
[R15.1] Risk & Compliance Officer (leave, public): 
[R15.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R15.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 16 ---
[R16.1] Risk & Compliance Officer (leave, public): 
[R16.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R16.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 17 ---
[R17.1] Risk & Compliance Officer (leave, public): 
[R17.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R17.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 18 ---
[R18.1] Risk & Compliance Officer (leave, public): 
[R18.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R18.3] Payer Contracting & Finance Manager (leave, public): 

--- Round 19 ---
[R19.1] Risk & Compliance Officer (leave, public): 
[R19.2] Pharmacy Clinical Lead (Anticoagulation Services) (leave, public): 
[R19.3] Payer Contracting & Finance Manager (leave, public): 

